Recent clinical experience with aldose reductase inhibitors.
Krans
H M
HM
Department of Endocrinology and Metabolic Diseases, University Hospital Leiden, The Netherlands.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D001706:Biopsy; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D048289:Imidazolidines; D009431:Neural Conduction / Q000187:drug effects; D010525:Peripheral Nerves / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D010793:Phthalazines / Q000627:therapeutic use*; D010919:Placebos; D014630:Vagus Nerve / Q000187:drug effects / Q000503:physiopathology
D007093:Imidazoles; D048289:Imidazolidines; D010793:Phthalazines; D010919:Placebos; C042829:ponalrestat; D000449:Aldehyde Reductase; C026411:sorbinil